Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Wound HealingSurgical WoundGraft Failure

Interventions

DRUG

RhPDGF-BB

0.3 mg/mL rhPDGF-BB

DRUG

Saline

Normal saline

Trial Locations (1)

RECRUITING

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

collaborator

Lynch Regenerative Medicine, LLC

UNKNOWN

lead

Vanderbilt University Medical Center

OTHER